Organogenesis Holdings

ORGO · NASDAQ

$1.02+$0.00 (+0.00%)TodayMarket closed · Oct 20, 7:48 PM ET

Prev close $1.02

ORGO analyst rating

BuyConsensus of 2 analysts over the last 12 months. 50% rate it a buy.

Strong buy0
Buy1
Hold1
Underperform0
Sell0

12-month price target · 3 analysts

Average $2.04 (+100.0% upside)

Low: $2.02
Now: $1.02
High: $2.10

Upgrades and downgrades

The latest rating actions, newest first

ORGO analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Truist Securities	Aug 7, 2026	Maintains	Hold	$3.00 → $2.00	33%
Truist Securities	May 28, 2026	Initiates	Hold	$3.00	33%
BTIG	Mar 26, 2026	Maintains	Buy	$8.00	48%
BTIG	Feb 27, 2026	Maintains	Buy	$9.00 → $8.00	48%
BTIG	Dec 26, 2025	Maintains	Buy	$9.00	48%
BTIG	Dec 15, 2025	Maintains	Buy	$9.00	48%
BTIG	Nov 20, 2025	Maintains	Buy	$7.00 → $9.00	48%

The case for and against

Updated Sep 15, 2026

Bull case

Organogenesis Holdings is in a strong position with its diverse portfolio of regenerative medicine products, including Apligraf and Dermagraft, which have demonstrated the ability to drive more rapid and significant healing in chronic wounds. Despite challenges in the current reimbursement landscape, the company is well positioned to grow in both the advanced wound care and surgical & sports medicine markets, with a potential market opportunity of $31 million for its product ReNu alone. Management has a clear focus on metrics that drive value creation, and the company's strong balance sheet and expected growth in margins make it a compelling investment opportunity for the long term.

Bear case

Organogenesis Holdings is facing multiple headwinds that could negatively impact its financial performance in the near future. These include the recent CMS reimbursement changes, which has led to a significant contraction in the company's end market, and the potential for further disruptions as smaller players exit the market. Additionally, the company's portfolio of regenerative medicine products may face challenges in gaining traction and utilization due to uncertainty around coding, coverage, and commercialization. These factors are likely to result in lower revenue and profitability for Organogenesis Holdings in the short term, with potential upside only expected from its ReNu product, which still faces regulatory and adoption challenges.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.